Wallace D J, Tumlin J A
Department of Medicine, Division of Rheumatology, Cedars-Sinai/UCLA School of Medicine, Los Angeles, USA.
Lupus. 2004;13(5):323-7. doi: 10.1191/0961203304lu1020oa.
LJP 394 (abetimus, Riquent, La Jolla Pharmaceuticals) is four oligonucleotide B cell toleragen which acts as an 'anti-anti DNA'. Given as a weekly infusion, Phase 1, 2, and 3 studies with this biologic on close to 1,000 patients have demonstrated no toxicity of any note. In patients with lupus nephritis and an elevated anti-DNA (Farr assay) who have a high affinity to LJP 394, the drug significantly decreases anti-DNA, improves quality of life, and trends towards reducing renal flares. LJP 394 is a promising induction and/or maintenance therapy for lupus patients with elevated anti-DNA and active disease.
LJP 394（阿贝替莫斯，瑞昆特，拉霍亚制药公司）是一种四聚体寡核苷酸B细胞耐受原，其作用相当于一种“抗抗DNA”物质。作为一种每周一次的静脉输注药物，针对近1000名患者开展的1期、2期和3期研究表明，该生物制剂无任何明显毒性。对于狼疮性肾炎且抗DNA水平升高（法尔测定法）且对LJP 394具有高亲和力的患者，该药物可显著降低抗DNA水平，改善生活质量，并呈降低肾脏炎症发作频率的趋势。LJP 394对于抗DNA水平升高且患有活动性疾病的狼疮患者是一种有前景的诱导和/或维持治疗药物。
